Stage 3 lymphoma means the cancer has spread to lymph node groups on both sides of the diaphragm, the thin muscle that separates your chest from your abdomen. It can also be classified as stage 3 if cancer is found in lymph nodes above the diaphragm and in the spleen. This stage applies to both Hodgkin and non-Hodgkin lymphoma, and while it represents advanced disease, the five-year relative survival rate for stage 3 non-Hodgkin lymphoma is about 74%.
How Stage 3 Is Defined
Lymphoma staging uses the Ann Arbor system (updated by the Lugano classification in 2014) to describe how far the cancer has spread through the body. The key landmark is the diaphragm. In stages 1 and 2, lymphoma is limited to one side of it. In stage 3, it has crossed to both sides, meaning affected lymph nodes exist in areas like the neck, chest, or armpits and also in the abdomen, pelvis, or groin.
The spleen plays a special role in staging. Because the spleen is part of the lymphatic system, cancer found there doesn’t automatically push the diagnosis to stage 4. Instead, lymphoma involving the spleen gets a suffix: stage IIIS. If there’s also localized spread into tissue directly next to an affected lymph node, that’s noted as IIIE. Both designations together would be IIIE,S. These suffixes help oncologists understand exactly where the disease is and plan treatment accordingly.
What Separates Stage 3 From Stage 4
The distinction between stage 3 and stage 4 comes down to where the cancer is growing. Stage 3 is still primarily a disease of the lymphatic system: lymph nodes and potentially the spleen. Stage 4 means lymphoma has spread to organs or tissues outside the lymphatic system entirely, such as the bone marrow, liver, or lungs. This is an important boundary because organ involvement changes both the treatment approach and the expected outlook.
The A and B Designations
You may see your stage written as 3A or 3B. The letter refers to whether you’re experiencing specific systemic symptoms known as “B symptoms.” These are:
- Unexplained fever
- Drenching night sweats
- Unexplained weight loss (more than 10% of body weight over six months)
If none of these are present, you’re classified as stage 3A. If you have one or more, it’s stage 3B. The B designation generally signals that the lymphoma is more active in the body, which can influence how aggressively treatment is approached. Some people with stage 3 lymphoma feel perfectly fine aside from swollen lymph nodes, while others deal with fatigue, fevers, and significant weight loss.
How Stage 3 Is Diagnosed
PET/CT scanning is the standard imaging tool for staging most lymphomas. It works by detecting areas of high metabolic activity, which cancer cells produce, while simultaneously creating detailed cross-sectional images of the body. This combination allows doctors to identify affected lymph nodes above and below the diaphragm and determine whether the spleen or nearby tissues are involved.
Some lymphomas don’t show up well on PET scans because they aren’t metabolically active enough. For these subtypes, diagnostic CT scans with contrast are used instead, relying on the size and appearance of lymph nodes rather than metabolic signals. When PET and CT results conflict in lymphomas that do show up on PET, the PET findings take priority. Staging also typically includes a biopsy (to confirm the lymphoma type and subtype) and blood work.
Treatment for Stage 3 Lymphoma
Treatment depends heavily on whether the lymphoma is indolent (slow-growing) or aggressive (fast-growing), not just the stage number. This is one of the more counterintuitive aspects of lymphoma: a slow-growing stage 3 lymphoma may require less immediate treatment than an aggressive stage 2.
For indolent (slow-growing) stage 3 lymphomas like follicular lymphoma, treatment options range widely. Some people start with watchful waiting, meaning no treatment at all until symptoms develop or the disease shows signs of progressing. When treatment is needed, it often involves targeted antibody therapy alone or combined with chemotherapy. Maintenance therapy, where targeted antibody treatments continue on a schedule after the initial treatment ends, is another common approach to keep the lymphoma in check over time. Radiation therapy targeting nearby lymph node groups is sometimes used as well.
For aggressive stage 3 lymphomas like diffuse large B-cell lymphoma, treatment typically begins right away. The standard approach combines targeted antibody therapy with multi-drug chemotherapy. These regimens are given in cycles over several months, and radiation may follow in some cases. Aggressive lymphomas grow quickly but also tend to respond more dramatically to treatment, which is why cure rates can be high even at advanced stages.
For some patients whose lymphoma returns after initial treatment or doesn’t respond well, stem cell transplant may be considered. This involves high-dose chemotherapy to eliminate the cancer, followed by an infusion of healthy stem cells to rebuild the bone marrow.
Survival Rates and Outlook
According to data from the National Cancer Institute’s SEER database (covering 2016 to 2022), the five-year relative survival rate for stage 3 non-Hodgkin lymphoma is 74%. That means people diagnosed at this stage are, on average, 74% as likely to be alive five years later as someone without the disease. About 17% of non-Hodgkin lymphoma cases are diagnosed at stage 3.
These numbers are population averages and vary significantly based on the specific subtype. An indolent lymphoma like follicular lymphoma has a very different trajectory than an aggressive one like mantle cell lymphoma, even at the same stage. Age, overall health, how well the cancer responds to initial treatment, and specific genetic features of the tumor all influence individual outcomes. Hodgkin lymphoma, in general, carries higher survival rates across all stages compared to most non-Hodgkin subtypes.
It’s also worth noting that survival statistics reflect treatments given years ago, since they track patients over a five-year window. Newer therapies continue to improve outcomes, so current numbers may underestimate the outlook for someone diagnosed today.